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Abstract
Background: Human memory CD4
+ T cells can be either CD300a/c
+ or CD300a/c
- and subsequent analyses
showed that CD4
+ effector memory T (TEM) cells are mostly CD300a/c
+, whereas CD4
+ central memory T (TCM) cells
have similar frequencies of CD300a/c
+ and CD300a/c
- cells.
Results: Extensive phenotypical and functional characterization showed that in both TCM and TEM cells, the
CD300a/c
+ subset contained a higher number of TH1 (IFN-g producing) cells. Alternatively, TH17 (IL-17a producing)
cells tend to be CD300a/c
-, especially in the TEM subset. Further characterization of the IL-17a
+ cells showed that
cells that produce only this cytokine are mostly CD300a/c
-, while cells that produce IL-17a in combination with
other cytokines, especially IFN-g, are mostly CD300a/c
+, indicating that the expression of this receptor is associated
with cells that produce IFN-g. Co-ligation of the TCR and CD300a/c in CD4
+ T cells inhibited Ca
2+ mobilization
evoked by TCR ligation alone and modulated IFN-g production on TH1 polarized cells.
Conclusion: We conclude that the CD300a/c receptors are differentially expressed on human TH1 and TH17 cells
and that their ligation is capable of modulating TCR mediated signals.
Background
Upon encounter with the antigen in secondary lymphoid
tissues, naïve CD4
+ T cells initiate a vigorous clonal
expansion. This expansion leads to the differentiation and
specialization into functionally distinct T helper (TH) cell
subsets or lineages. Each TH subset is involved in tailoring
immune responses specific to a wide range of antigens.
They are characterized by the expression of specific cell
surface receptors, and distinct transcription factors that
lead to the secretion of a particular set of cytokines [1].
For example, TH1 cells express the transcription factor
T-bet and secrete IFN-g,T N F - a and IL-2. They also
express the chemokine receptors CCR5 and CXCR3 and
the cytokine receptors IL-12Rb2 and IL-18Ra.T H1 cells
play an important role in the resistance against intracellu-
lar pathogens and in the pathogenesis and maintenance of
certain autoimmune diseases [2-13]. Another TH subset,
TH17 cells, express the transcription factor RORgt, secrete
IL-17a, IL-17f and IL-22 and are characterized by the
expression of the chemokine receptor CCR6, the cytokine
receptors IL-23R and IL-1R1 and the C-type lectin recep-
tor CD161. TH17 cells play a very important role in the
defense against extracellular pathogens and in the patho-
genesis of autoimmune diseases [14-22]. Other TH subsets
include TH2, T follicular helper (TFH) and induced regula-
tory T (iTreg) cells [1,23]. The classical view of distinct
and terminally differentiated lineages is currently chal-
lenged by many findings showing a degree of plasticity
and flexibility in the TH subsets that can be represented as
a series of transitions from less to more stable states
[24-26]. Furthermore, there are many CD4
+ T cells that
do not fit the profile of the subsets described above in that
they produce cytokines ascribed to more than one lineage.
For instance, some human IL-17a or IL-4 producing cells
were found to also produce IFN-g [14,27-29]. Additionally,
TH subsets can also be subdivided according to the expres-
sion of cell surface receptors. We have previously reported
that the expression of CD300a/c distinguishes a subset of
TH1 cells that is more polyfunctional and, after stimula-
tion, up-regulates the T-box transcription factor Eomeso-
demin [30].
CD300a is an immunomodulatory receptor that
belongs to the CD300 family of activating/inhibitory
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that has three classical immunoreceptor tyrosine-based
inhibitory motifs (ITIMs) and one non-classical ITIM in
its cytoplasmic tail and a single V-like Ig extracellular
domain. This receptor is expressed on cells of both
myeloid and lymphoid lineages and the ligand is not
known [31]. Several in vitro studies have shown that
CD300a ligation is capable of inhibiting the eosinophil
response to eotaxin and IL-5 [32], NK cell mediated
cytotoxicity [33,34], B cell receptor (BCR) mediated
Ca
2+ mobilization and NFAT translocation [35], FcεRI
mediated activation of mast cells [36] and FcgRIIa
mediated Ca
2+ flux and reactive oxygen species (ROS)
production in neutrophils [37]. In vivo studies have also
shown the inhibitory potential of CD300a. For instance,
t r e a t m e n to fm i c ew i t hab i s p e c i f i ca n t i b o d yl i n k i n g
CCR3 to CD300a reversed remodeling and airway
inflammation in a model of asthma [38]. Furthermore,
genetic studies have revealed that a non-synonymous
mutation in the CD300a extracellular domain is linked
to psoriasis susceptibility [39] and that is implicated in
the development of Alzheimer’s disease [40]. Other stu-
dies have shown that circulating CD4
+CD45RO
+ T cells
exhibit lower expression of CD300a/c in psoriasis patients
compared with healthy donors [41]. The expression of
CD300a/c is also down-regulated in B cells from HIV
infected patients, suggesting that this receptor may contri-
bute to the B cell dysfunction observed in HIV induced
immunodeficiency [35]. CD300a, along with three other
genes, has been identified as a blood biomarker that can
be used for the differentiation of patients with ulcerative
colitis from patients with Crohn’s disease and noninflam-
matory diarrhea [42].
It has been previously shown by real time PCR that both
receptors, CD300a and CD300c, are expressed on human
CD4
+ T cells [41]. However, with the available monoclonal
antibodies it is impossible to distinguish CD300a from
CD300c on the cell surface [34]. The extracellular domains
of CD300a and CD300c are highly homologous, showing
80% identity [31,34]. While the transmembrane region of
CD300c contains a charged amino acid that is important
for its association with the immune receptor tyrosine-
based activation motif (ITAM) bearing FcεRg chain, and
therefore delivers activating signals [43], CD300a, as men-
tioned above, transmits inhibitory signals through the
ITIMs containing intracellular tail [34].
In this report, using the anti-CD300a/c E59.126 mAb,
we show that CD300a/c is preferentially expressed on
CD4
+ effector memory T (TEM)c e l l s .W es h o wt h a tC D 4
+
T cells producing only IL-17a are mostly CD300a/c
- while
CD4
+ cells producing IL-17a in combination with other
cytokines, such as IFN-g,T N F - a and/or IL-2 are mostly
CD300a/c
+. Furthermore, we investigate the ability of
CD300a/c receptors to modulate TCR mediated Ca
2+ flux
and IFN-g production of TH1 polarized cells.
Results
CD300a/c is highly expressed on TEM CD4
+ T cells
A recent manuscript has reported that CD300a and
CD300c are impossible to distinguish on the cell surface,
using a panel of mAbs [34]. Therefore, we first tested the
binding specificity of the E59.126 mAb, an antibody pre-
viously described as CD300a specific [30,32,33,35-37,44].
Our results showed that this antibody recognizes both
CD300a and CD300c receptors on transiently transfected
293T cells (data not shown). Consequently, hereafter we
will refer as CD300a/c
+ to cells that specifically bind the
E59.126 mAb.
We have previously published that naïve CD4
+ T cells
express low amounts of CD300a/c, whereas memory
CD4
+ T cells can be subdivided into CD300a/c
+ and
CD300a/c
- populations [30]. However, it is not known if
within the memory CD4
+ T cells there are differences in
the expression of CD300a/c between the CD4
+ effector
memory (TEM) and central memory (TCM) cells. We used
three staining strategies to delineate the expression of
CD300a/c by TEM and TCM CD4
+ T cells. Each one of
these strategies is based on the combination of two mar-
kers: CD45RA and CCR7 [45], CD45RO and CD62L [46],
or CD45RO and CD27 [45,47]. Our results show that TEM
cells, characterized by the phenotype CD45RA
-CCR7
-,
CD45RO
+CD62L
- or CD45RO
+CD27
-, are predominantly
CD300a/c
+ (~70%), whereas TCM cells, defined by the phe-
notype CD45RA
-CCR7
+, CD45RO
+CD62L
+ or CD45RO
+CD27
+, have similar percentage of CD300a/c
+ and
CD300a/c
- cells (Figure 1).
CD300a/c expression in cytokine producing TCM and TEM
CD4
+ T cells
Cell surface receptors have been used as markers to iden-
tify different TH subsets. While not exclusive, expression
of CXCR3 and CCR5 is associated with TH1 cells [1,7,9];
CCR3, CCR4 and CRTh2 with TH2 cells [1,7,9]; and
CCR4, CCR6 and CD161 with TH17 cells [1,14,17,20]. We
have previously found that IFN-g (TH1) producing cells
are predominantly CD300a/c
+ and that both IL-4 (TH2)
and IL-17a (TH17) producing CD4
+ T cells are equally dis-
tributed between the CD300a/c
+ and CD300a/c
- subsets
[30]. To determine if CD300a/c expression could be uti-
lized to further discriminate among TH subsets, we tested
for the expression of CD300a/c in TCM and TEM cytokine
producing cells. In these experiments, we classified CD4
+
memory cells as those expressing CD45RO and CD27
because these markers remained stably expressed after the
in vitro stimulation with PMA and ionomycin, whereas
the expression of other receptors such as CD62L decreases
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in both the TCM (CD45RO
+CD27
+)a n dt h eT EM
(CD45RO
+CD27
-) subsets are mainly CD300a/c
+.O nt h e
other hand, TCM cells that produce IL-4 were only slightly
enriched in the CD300a/c
+ subset, whereas the TEM IL-4
producing cells showed no tendency to express or not
express CD300a/c. TEM cells that produce IL-17a
expressed somewhat less CD300a/c, whereas the TCM
IL-17a producing cells showed no tendency to express or
not express CD300a/c. Analysis for IL-2 and TNF-a pro-
duction demonstrated that TCM cells producing these
cytokines tend to be CD300a/c
+ (Figure 2B).
CD300a/c is differentially expressed by CD4
+ T cells that
produce IFN-g and IL-17a
Our results show that cells that produce IFN-g are mostly
CD300a/c
+ (Figure 2 and [30]), while more IL-17a produ-
cing cells are CD300a/c
-. Several studies have shown that
there is a significant portion of cells that produce both
cytokines [14,27]. Given the association between IFN-g
production and CD300a/c expression, we reasoned that
the production of IFN-g by some IL-17a producing cells
could account for the presence of IL-17a producing cells
in the CD300a/c
+ subset. In fact, we observed that the
IFN-g
+IL-17a
+ cells are enriched in the CD300a/c
+ subset
at levels similar to the percentage present for IFN-g
+IL-
17a
- cells, while the IFN-g
-IL-17a
+ cells tend to be
CD300a/c
- (Figure 3A). In agreement with our observa-
tion of the correlation between CD300a/c expression and
IFN-g production [30], we also observed that cells in the
CD300a/c
+IL-17a
- subset produce the largest amounts of
IFN-g and the CD300a/c
+IFN-g
+ subset produce the low-
est levels of IL-17a on a per cell basis, as indicated by the
mean fluorescence intensity (MFI) (Figure 3A). The MFI
of cytokine staining is a value known to be correlated
with the amount of cytokine produced by a T cell [49].
This, together with our previously published results [30],
indicates that CD300a/c expression is a marker for cells
Figure 1 Flow cytometric analysis of human peripheral blood CD4
+ T cells. The expression of CD300a/c on central (TCM)a n de f f e c t o r
memory (TEM) CD4
+ T cells was determined with three staining strategies: CD45RO and CD62L (upper panels), CD45RO and CD27 (middle
panels) and CD45RA and CCR7 (lower panels). A representative donor is shown for each staining. Bar graphs represent the average ± SEM of the
percentage of CD300a/c
+ cells within TCM and TEM. Results shown are from 12 healthy donors.
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IFN-g
+IL-17a
+ cells are predominately CD300a/c
+ (Figure
3B). Similar to IFN-g,T N F - a production is also corre-
lated with CD300a/c expression when both TNF-a and
IL-17a production were analyzed and the TNF-a
-IL-17a
+
cells tend to be CD300a/c
- (Figure 3C).
We further explored the notion that cells producing IL-
17a alone tend to be CD300a/c
-. To do this, we analyzed
CD300a/c expression on CD4
+ cells producing IL-17a
alone or in combination with two other cytokines (Figure
4). We analyzed cells that produce IL-17a, IFN-g and
TNF-a (Figure 4A), IL-17a, IFN-g and IL-2 (Figure 4B)
and cells that produce IL-17a, TNF-a and IL-2 (Figure
4C). We found that cells producing IL-17a alone tend to
be CD300a/c
-, whereas cells producing IL-17a plus one or
two additional cytokines tend to be less CD300a/c
-. More
importantly, we found that the IL-17a producing cells that
also produce IFN-g tend to be enriched in the CD300a/c
+
subset (Figure 4A and 4B).
Ligation of CD300a/c with the E59.126 mAb modulates
TCR mediated signals on human CD4
+ T cells
Human CD300a and CD300c are two highly homolo-
gous receptors expressed on cells of both lymphoid and
myeloid lineages with opposing signaling capabilities
[31]. Ligation of these receptors with mAb is known to
modulate activation signals on a variety of cells, includ-
ing NK cells, neutrophils, mast cells, B cells and eosino-
phils [32-34,36,37]. Although several studies have shown
that CD300a/c
+ and CD300a/c
- CD4
+ T cells have dif-
ferent features [30,41], to our knowledge there is no
report addressing the modulatory role of ligating
CD300a and CD300c on TCR mediated signaling. To
determine if CD300a/c are capable of regulating human
T cell activation signals, we generated CD4
+ T cell lines
from healthy donors that express high levels of this
receptor and measured intracellular Ca
2+ flux. Co-liga-
tion of TCR and CD300a/c with mAbs resulted in a sig-
nificant decrease in intracellular Ca
2+ flux, indicating
that CD300a/c ligation down-modulates TCR mediated
signals (Figure 5). Given that IFN-g producing cells tend
to be CD300a/c
+ we asked the question if ligation of
CD300a/c with the E59.126 mAb can modulate the pro-
duction of this cytokine in response to TCR stimulation.
To do this, we polarized purified CD4
+ T cells under
TH1 conditions and tested for IFN-g production. Results
shown in Table 1 illustrate that compared with ligation
of the TCR alone, co-ligation of the TCR and CD300a/c
Figure 2 Flow cytometric analyses of stimulated CD4
+ Tc e l l s .P u r i f i e dC D 4
+ T cells were stimulated with PMA and ionomycin for 4-5 h in
the presence of GolgiStop (monensin). The expression of CD300a/c was determined in the TCM (CD45RO
+CD27
+) and TEM (CD45RO
+CD27
-)
cytokine producing cells. A representative healthy donor is shown for (A) the IFN-g, IL-4 and IL-17a, and (B) IL-2 and TNF-a producing cells. Each
graph represents the percentage of CD300a/c
+ and CD300a/c
- TCM and TEM cells that produce a given cytokine. Each symbol corresponds to a
different donor.
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+ T cells. (A) Purified CD4
+ T cells were stimulated
with PMA and ionomycin for 4-5 h in the presence of GolgiStop (monensin). Then, cells were stained for intracellular production of IFN-g and IL-
17a, and cell surface expression of CD300a/c. Analysis of cells from a representative donor is shown. The bar graphs represent the average ±
SEM of the percentage of CD300a/c
+ cells within the cytokine producing cells and the average ± SEM of the MFI of IFN-g expression and IL-17a
expression within the cytokine producing cells. Results are from 11 healthy donors. (B) Percentage of cells producing both IFN-g and IL-17a
within the IL-17a producing CD45RO
+CD300a/c
+ and CD45RO
+CD300a/c
- subsets is shown. Analysis of cells from a representative donor (left)
and a graph (right) with the results for all donors are presented. (C) The experiments are the same as in A and B, except cells were stained for
intracellular production of TNF-a and IL-17a.
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-. Purified CD4
+ T cells were stimulated with PMA and ionomycin for 4-5 h in the
presence of GolgiStop (monensin). Then, cells were stained for cell surface expression of CD300a/c and intracellular production of IL-17a and
other cytokines. A representative donor is shown for (A) IL-17a, for TNF-a and IFN-g producing cells, (B) IL-17a, IL-2 and IFN-g producing cells,
and for (C) IL-17a, IL-2 and TNF-a producing cells. Graph bars represent the average ± SEM of the percentage of CD300a/c
+ cells within the
cytokine producing cells. Results are from 8-12 healthy donors.
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2+ flux. CD4
+ T cell lines were generated from healthy donors. Cells were loaded with Fluo-4
and Fura-Red. Then, cells were acquired in a flow cytometer, and after a baseline reading of 30 s, anti-CD3 plus anti-CD300a/c mAb or anti-CD3
plus isotype control mAb (black arrows) were added. Goat anti-mouse Ab was added 30 s later to cross-link the primary mAb (grey arrows).
Intracellular Ca
2+ concentration was measured by the ratio of Fluo-4/Fura Red as a function of time.
Simhadri et al. BMC Immunology 2011, 12:62
http://www.biomedcentral.com/1471-2172/12/62
Page 7 of 11inhibited TCR mediated production of IFN-g by CD4
+ T
cells from three separate donors, but increased the num-
ber of IFN-g
+ cells in two donors. These results demon-
strate that ligation of CD300a/c with the E59.126 mAb
is capable of modulating TCR mediated responses.
Discussion
For the past 10-15 years, a remarkable effort has been
dedicated to the comprehensive phenotypic and functional
characterization of human T cell subsets [50,51]. In addi-
tion to the cytokines that CD4
+ T cell subsets secrete, they
also express a relatively specific pattern of chemokine
receptors. For instance, while CCR5 and CXCR3 expres-
sion is associated with TH1 cells [1,7,9], CCR4 and CCR6
expression is associated with TH17 cells [1,14]. In general,
the association between the expression of cell surface
receptors and intracellular cytokines implies that T cell
subsets exhibit differential requirements for effector func-
tions, homing potential, survival and stimulation. How-
ever, it should be noted that the broad correlation
between cell surface receptor expression and cytokine pro-
duction patterns is far from perfect [50]. Furthermore, the
existence of CD4
+ T cells that are able to produce two or
more cytokines ascribed to different lineages complicates
the classical view of distinct subsets [14,27,29]. Another
important question, that recently is under intense investi-
gation, is one of T cell plasticity or flexibility, implying
that CD4
+ T cell subsets are more appropriately viewed as
works in progress rather than terminally differentiated
cells [24-26]. For instance, studies in humans have shown
the plasticity of TH17 cells and their ability to switch into
TH1 cells, a process that is mediated by IL-12 [24,27,52].
Cell plasticity or flexibility may arise from heterogeneous
populations or, alternatively, from flexible genetic pro-
grams [25,26].
In addition to chemokine receptors, other cell surface
markers have been ascribed to specific CD4
+ Tc e l ls u b s e t s .
For instance, all human TH17 cells express CD161 [17,53].
Also, we have previously reported that in peripheral blood
the majority of IFN-g producing cells are CD300a/c
+,
although there was a degree of variability [30]. Neverthe-
less, the TH1 cells that are CD300a/c
+ are characterized by
their higher production of IFN-g on a per cell basis and
their tendency to be polyfunctional in regard to cytokine
production [30]. One of the most groundbreaking classifi-
cations of memory T cells was proposed by Sallusto and
colleagues. They identified two subsets, TCM and TEM cells,
that are distinguished according to the surface expression
of CD45RA and CCR7 [45]. Our results show that both
TEM and TCM CD4
+ T cells can be further subdivided into
two subsets based in their CD300a/c expression. We have
found that TEM CD4
+ T cells have a higher frequency of
CD300a/c
+ cells than TCM CD4
+ T cells. The finding that
memory CD4
+ T cells can be divided into two populations
based on their level of CD300a/c expression raises the pos-
sibility of a functional dichotomy related to the level of this
expression. In fact we show that CD300a/c
+ cells, both in
the TCM and TEM subsets, harbor a higher frequency of
IFN-g producing cells than the CD300a/c
- TEM and TCM
CD4
+ T cells, which is in agreement with our previous
published results showing that TH1 cells are mostly, but
not entirely CD300a/c
+ [30]. Analysis of IL-2 and TNF-a
producing cells also show that CD300a/c
+ cells show a
higher frequency of cytokine producing cells, although this
increase is restricted to the TCM CD4
+ cells. On the other
hand, the CD300a/c
- subset in the TEM CD4
+ T cells tends
to have a higher number of IL-17a producing cells than the
CD300a/c
+ cells. In light of this differential CD300a/c
expression in the IFN-g and IL-17a producing cells, we
decided to study the expression of this marker on IL-17a
producing cells in more detail. Our results show two
important findings: first that in ex vivo stimulated periph-
eral blood CD4
+ T cells from healthy donors the IFN-g
producing cells are mostly CD300a/c
+, independently if
they produce only IFN-g or IFN-g plus IL-17a; and second
that, on a per cell basis, the higher IFN-g producers are
CD300a/c
+ and do not produce IL-17a at the same time,
while the lower IL-17a producers are CD300a/c
+ and pro-
duce at the same time IFN-g. This suggests that the IFN-g
and IL-17a higher producers cells are mostly, although not
entirely, exclusive and that this correlates with the cell sur-
face expression of CD300a/c. In addition to other factors,
this probably reflects the effect of TGF-b1 in vivo, as this
cytokine has been shown to down-regulate CD300a/c
Table 1 Percentage of IFN-g producing cells
cIgG1
1 Anti-CD300a/c
1 cIgG1
1 Anti-CD300a/c
1
DONORS Anti-CD3 (0.1 μg) Anti-CD3 (0.1 μg) Anti-CD3 (0.5 μg) Anti-CD3 (0.5 μg)
D1 27 21 42 37
D2 22 23 24 24
D3 11 7 9 9
D4 15 8 31 22
D5 13 17 23 28
D6 35 37 46 55
1Isotype control (cIgG1) and anti-CD300a/c mAb are used at a constant concentration of 5 μg per well.
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the generation of TH17 cells [30]. Although additional stu-
dies are required to further define CD300a/c
+ and
CD300a/c
- TH1a n dT H17 cells, to elucidate for example
the degree of plasticity or flexibility of the two TH17 cell
subsets, our observation that CD300a/c is differentially
expressed on these subsets adds another layer of complex-
ity to the growing field of human TH cell subsets [1,25,26].
Here we show that cross-linking of CD300a/c and TCR
with mAbs is capable of modulating signals evoked by
TCR ligation alone. Results presented in Table 1 show
that co-ligation of the TCR and CD300a/c inhibited TCR
mediated IFN-g production on polarized TH1 cells in three
donors while there was an increase in the frequency of
IFN-g
+ cells in two donors. These results are reminiscent
of those published by Lankry et al [34]. These authors
showed that CD300a is indeed an inhibitory receptor able
to inhibit human NK cell mediated killing, despite the fact
that some NK cell clones were not inhibited in a CD300a
dependent manner. They proposed that the absence of the
inhibitory signal on those clones was probably due to the
presence of CD300c on NK cells that was also recognized
and ligated by the same mAbs they used [34]. We believe
that this potential ligation of either receptor also may
account for the results we have obtained, since we have
found that the E59.126 mAb recognizes CD300a and
CD300c (data not shown). Both receptors were previously
shown to be expressed on human CD4
+ T cells, at least at
the transcript levels [41]. Furthermore, the recent discov-
ery that CD300c is able to interact and form heterocom-
plexes with other members of the CD300 family, including
CD300a, adds another degree of complexity in the signal-
ing pathways that emanate from these two receptors [43].
Human CD4
+ T cells express CD300a and CD300c [31,41]
and it may be expected that, depending on the relative
expression of each one of these receptors, the signaling
outcome after ligation with anti-CD300a/c mAbs, could
be different depending on the donors. Clearly, further
investigation is required to be done in this regard, and the
generation of extensively tested specific mAbs that are
able of discriminating both CD300a and CD300c is
necessary.
Conclusions
Taken together, we show that ex vivo isolated human TH1
and TH17 cells differentially express CD300a/c, probably
reflecting the different requirements for the in vivo genera-
tion of both TH subsets. Moreover, we show for the first
time that ligation of CD300a and CD300c with the
E59.126 mAb has an immunomodulatory role on human
CD4
+ T cells as revealed by its ability to modulate TCR
mediated Ca
2+ flux and IFN-g production. Better under-
standing of the role of the different TH subsets based on
their CD300a/c expression might be useful for innovative
drug development and disease management in the future.
Methods
Study population
Buffy coats were obtained from the National Institutes of
Health (NIH) blood bank from healthy donors. All study
subjects provided written informed consent, in accordance
with the Institutional Review Boards of the NIH and the
Food and Drug Administration (FDA). FDA specifically
approved this study under RIHSC protocol 08-070D.
Reagents
Antibodies and reagents used in this study were obtained
from the following vendors: purified and PE-Cy7 anti-CD3
(clone UCHT1), purified anti-CD28 (clone CD28.2), PE-
Cy7 and APC anti-CD4 (clone RPA-T4), APC anti-CD27
(clone 0323), APC anti-CD45RA (clone HI 100), FITC,
PE-Cy7 and APC anti-CD45RO (clone UCHL1), APC
anti-CD62L (clone Dreg56), FITC and APC anti-IL-2
(clone MQ1-17H12), FITC anti-IL-4 (clone MP4-25D2),
FITC anti-IL-17a (clone eBio84DEC17), PE-Cy7 and APC
anti-TNF-a (clone Mab11) from eBioscience. PE-Cy7 and
Alexa Fluor 647 anti-IFN-g (clone B27) are from BD Bios-
ciences. Purified and PE anti-CD300a/c (clone E59.126)
are from Beckman-Coulter. FITC anti-CCR7 (clone
150503) is from R&D Systems. Goat anti-mouse (GAM)
IgG and isotype control IgG1 from Jackson ImmunoRe-
search Laboratories. Recombinant IL-2 was obtained from
the NCI and recombinant IL-12 from R&D Systems. Fluo-
4 and Fura-Red were obtained from Invitrogen. PMA and
Ionomycin were purchased from Sigma. BD Cytofix/Cyto-
perm Plus kit with GolgiStop (monensin) was used for
intracellular cytokine detection and was purchased from
BD Biosciences.
Cell activation assays and intracellular staining
Human CD4
+ T cells were isolated from buffy coats by
negative selection with a kit from Miltenyi Biotec (purity
was > 93%). For activation experiments, purified CD4
+ T
cells were cultured in T cell medium: IMDM medium
(Invitrogen) containing 10% human AB serum (Valley Bio-
medical) and supplemented with GlutaMAX (Invitrogen).
Cells were stimulated with PMA (50 ng/ml) plus Ionomy-
cin (2 μM) for 4-5 h. GolgiStop (monensin) was added to
the cells at the same time than PMA and Ionomycin.
Then, cell surface receptor expression and intracellular
cytokine staining were determined with the BD Cytofix/
Cytoperm Plus kit following the manufacturer instruc-
tions. A second set of experiments was performed with
purified CD4
+ T cells that were polarized under TH1 con-
ditions. Cells were cultured in a 12 well plate pre-coated
with 1 μg of anti-CD3 and 5 μg anti-CD28 mAb. Four ml
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Page 9 of 11of cells at a concentration of 1 × 10
6/ml were added to the
plate and cultured in T cell medium containing 100 U/mL
of IL-2 and 10 ng/mL of IL-12. After three days, cells were
transferred to non-coated plates adding fresh medium
containing cytokines if necessary. At day 8, cells are
washed and resuspended in T cell medium containing
GolgiStop at a density of 0.5-1 × 10
6/ml. Two ml of cells
were added to each well of a 24 well plate coated with dif-
ferent amounts of anti-CD3, anti-CD300a/c and isotype
control IgG1 mAb and incubated for 6-7 h in the presence
of GolgiStop (monensin). Then, intracellular IFN-g was
determined with the BD Cytofix/Cytoperm Plus kit. Flow
cytometry experiments were performed with a FACS Cali-
bur cytometer (BD Biosciences) and the data were ana-
lyzed using the FlowJo software package (Treestar).
Lymphocytes were electronically gated based on the side
and forward scatter parameters.
Ca
2+ flux assay
Primary human CD4
+ T cell lines were obtained by cul-
turing freshly isolated cells in 24 well plates coated with
anti-CD3 (1 μg/well) plus anti-CD28 (5 μg/well) mAbs
and 100 U/ml of recombinant IL-2. Cells were re-stimu-
lated weekly and used for Ca
2+ flux experiments during
the third or fourth week. CD4
+ T cell lines were washed
and resuspended in HBSS (Invitrogen) with 1% FCS at
5×1 0
6 cells/ml and labeled with Fluo-4 (2 μg/ml) and
Fura Red (5 μg/ml) for 30 min at 30°C. Cells were
washed twice and resuspended at 2 × 10
6 cells/ml. Prior
to activation, cells were incubated at 37°C for 5 min in a
water bath, followed by acquisition for 30 s in a FACS
Calibur cytometer to establish a baseline. Then, primary
mAb were added, and acquisition of cells was continued
for 30 s. At this point, primary mAb were cross-linked
with goat anti-mouse (GAM) IgG and acquisition was
c o n t i n u e df o r5 - 6m o r em i n .D a t aw e r ea n a l y z e du s i n g
the FlowJo software package.
Statistical analysis
Quantitative data were analyzed using GraphPad Prism
software. The data were plotted as bar graphs or scatter
plots, and pair wise comparisons were examined by two-
tailed paired Student’s t-test with 99% of confidence inter-
val. P < 0.05 was considered significant.
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